The Court of Appeals (CA) has denied Sanofi Pasteur’s motion for reconsideration regarding its Dengvaxia dengue vaccine, upholding a previous decision that revoked the vaccine’s certificates of product registration (CPRs) in 2018.
The revocation followed Sanofi’s 2017 disclosure that Dengvaxia posed risks to individuals who had not previously contracted the virus, leading the Philippine government to halt its national vaccination program.
In a resolution dated September 20, the CA dismissed Sanofi’s petition for review, reaffirming the permanent revocation of the CPRs.
Associate Justice Eduardo Ramos Jr. noted that the arguments presented in the motion had already been deemed without merit.
As a result, the ban on Dengvaxia remains in effect.
Source: PhilNews24 | September 26, 2024
SANOFI’S DENGVAXIA APPEAL DISMISSED BY COURT OF APPEALS
Latest from News
President Ferdinand Marcos Jr. has signed Republic Act 12312, officially banning Philippine offshore gaming operators (POGOs)
The Metropolitan Manila Development Authority (MMDA) announced it will suspend the number coding scheme on October
The Bureau of Immigration (BI) announced it will hire additional officers ahead of the Christmas and
The Philippine National Police (PNP) announced it will investigate violations of President Marcos Jr.’s price freeze
The Philippine Conference on Women, Peace, and Security (WPS) kicked off on October 28 at the